T-Cell Lymphoma Clinical Trials

A listing of T-Cell Lymphoma medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 53 clinical trials
Pembrolizumab and Radiotherapy for Patients With NK/T Cell Lymphoma

limited stage NK/T cell lymphoma who are not eligible to chemotherapy. It is planned to enroll 30 patients in chinese sites. All eligible patients will be treated with standard radiotherapy

  • 0 views
  • 21 Apr, 2022
PK and ECG Determinations Following 8 Weeks of HyBryte Treatment for Cutaneous T-Cell Lymphoma

To assess the blood levels of hypericin and any electrocardiogram (ECG) changes during 8 weeks of HyBryte (topical hypericin ointment) photodynamic therapy.

  • 0 views
  • 26 May, 2022
  • 1 location
A Study to Investigate CYC140, in Subjects With Advanced Solid Tumors and Lymphoma

This is a 2-part, phase 1/2, open-label, multicenter study designed to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, pharmacogenomics, and efficacy of CYC140 administered orally daily. This study consists of Phase 1 and Phase 2 components in subjects with advanced solid tumors and lymphoma who have progressed despite having standard therapy …

  • 0 views
  • 09 May, 2022
  • 2 locations
A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

This clinical trial will study brentuximab vedotin with CHP to find out if the drugs work for people who have certain types of peripheral T-cell lymphoma (PTCL). It will also find out what side

leukemia
prednisone
cancer
angioimmunoblastic t-cell lymphoma
avid
  • 0 views
  • 24 May, 2022
  • 39 locations
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies

This study evaluates the efficacy, safety and pharmacokinetics of tinostamustine (EDO-S101) in patients with relapsed/refractory hematologic malignancies. All patients will receive tinostamustine.

hodgkin's disease
sezary syndrome
metastases
t-cell lymphoma
fungal infection
  • 0 views
  • 05 May, 2022
  • 15 locations
Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

This study will characterize the safety and clinical benefit of valemetostat tosylate in participants with relapsed/refractory peripheral T-cell lymphoma, including relapsed/refractory adult T

  • 0 views
  • 25 May, 2022
  • 58 locations
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer

This trial will look at a drug called SEA-TGT (also known as SGN-TGT) to find out whether it is safe for patients with solid tumors and lymphomas. It will study SEA-TGT to find out what its side effects are. A side effect is anything the drug does besides treating cancer. …

avid
systemic therapy
cancer chemotherapy
stem cell transplantation
salvage therapy
  • 102 views
  • 15 May, 2022
  • 29 locations
CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

This is a research study to determine the safety and tolerability of ATLCAR.CD30 for treating relapsed/refractory Peripheral T Cell Lymphoma. Blood samples will be collected from study

cancer
hysterectomy
t-cell lymphoma
peripheral t-cell lymphoma
cyclophosphamide
  • 0 views
  • 13 Apr, 2022
  • 2 locations
Deep Phenotyping of Cutaneous T Cell Lymphoma, Type Mycosis Fungoides

Mycosis fungoides (MF) is an ultra-orphan disease of which the etiology remains unknown. MF is diagnosed by correlating clinical appearance with histopathological analysis of often multiple invasive skin punch biopsies. To move patient care and the development of novel treatments for MF forward, objective, sensitive and reliable tools that are …

psoriasis
methotrexate
Accepts healthy volunteers
immunosuppressive therapy
mycosis
  • 0 views
  • 26 Apr, 2022
  • 1 location
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma

transplant may result in fewer problems and side effects. Eligibility Recipients: People ages 12 and older with peripheral T cell lymphoma that does not respond to

granulocyte colony stimulating factor
colony stimulating factor
ejection fraction
t-cell lymphoma
therapeutic agents
  • 15 views
  • 24 May, 2022
  • 2 locations